The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published Date: Dec 14, 2015

Abstract

INTRODUCTION: We sought to investigate the impact of fatty liver disease (FLD) on prostate cancer (PCa) screening by estimating the odds of having a prostate-specific antigen (PSA) value over the cutoff used to prompt for the recommendation of prostate biopsy.

Authors

  • Jong Hyun Yoon
    Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;
  • Hee Jo Yang
    Department of Urology, Cheonan Hospital, Soonchunhyang University, College of Medicine, Cheonan, Korea.
  • Jae Heon Kim
    Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;
  • Seung Whan Doo
    Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;
  • Won Jae Yang
    Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;
  • Jiyoung Hwang
    Department of Radiology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;
  • Seong Sook Hong
    Department of Radiology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;
  • Suyeon Park
    Department of Biostatistics, Soonchungyang University, College of Medicine, Seoul, Republic of Korea;
  • Dae Yeon Cho
    Department of Urology, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals